Vernx Biotechnology aims to be the global leader in commercialising nutritional products aimed at reducing necrotising enterocolitis and other gut disorders in premature infants.
iCrowdNewswire -
Jul 7, 2016 11:38 AM ET
Vernx Biotechnology
Helping premature infants thrive.
Company Summary
Vernx Biotechnology aims to be the global leader in commercialising nutritional products aimed at reducing necrotising enterocolitis and other gut disorders in premature infants. Vernx will be the first company in the APAC region to sell human donor milk and human milk fortifier to hospitals. In addition we will commercialise a novel fatty acid to help improve gut disease in premature infants. Vernx is owned by the two founders.
Biotechnology innovator with over 20 years experience. Chief innovation officer at Clover Corporation. Leader in the spin out of IP related to premature infant nutrition. Founding Director of commercial development at Premneo pharmaceuticals. Craig is also Co-Founder and Director of a social enterprise, Feedback Nutrition.
10 years of product development experience with Clover Corporation. Co-inventor of Premneo DHA oral solution used in largest premature infant trial in collaboration with Women’s and Children’s hospital Adelaide. She is also Co-Founder and Director of a social enterprise, Feedback Nutrition.